by The basal insulin market comprises basal or long-acting insulins that are designed to mimic the basal or background insulin secretion by the pancreas. These insulins are used for maintaining normal blood glucose levels between meals and overnight. Leading basal insulins available in the market are Lantus and Levemir. They provide around-the-clock insulin coverage with a constant level of insulin delivery. Basal insulin products are convenient to use and help people with Type 1 and Type 2 diabetes manage their condition through continuous insulin treatment.
The Global Basal Insulin Market is estimated to be valued at US$ 18.78 Mn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the basal insulin market are 3M Company, Turtle Wax, Inc., Meguiar’s, Inc., Simoniz USA, Inc., WD-40 Company, Quixx GmbH, Langka Corporation, Scholl Concepts GmbH, Würth Group, BARDAHL Manufacturing Corporation, Gtechniq Ltd., Mothers Polishes, Waxes and Cleaners, SONAX GmbH, Chemical Guys. Companies are focused on developing new basal insulin formulations with improved safety and efficacy profiles to gain market share.
The growing prevalence of diabetes worldwide is a key factor driving demand for Global Basal Insulin Market Trends As per estimates, approximately over 500 million people are likely to be suffering from diabetes by 2030. Moreover, growing awareness about diabetes treatments and management is further propelling the basal insulin market.
Major players are expanding their geographic reach through collaborations and acquisitions of regional players. This allows them to strengthen their market position and cater to the needs of an increasing diabetic patient pool globally.
Market Key Trends
The increasing adoption of home care settings for diabetes management is one of the key trends in the basal insulin market. Home-based insulin delivery solutions offer improved patient comfort and convenience over hospital-administered injections. This is expected to positively impact the demand for basal insulins in the coming years. Manufacturers are developing innovative self-care products like insulin pens, pumps, and smart insulin delivery devices optimized for self-administration.
Porter’s Analysis
Threat of new entrants: The basal insulin market requires huge capital investment for research and development of new drugs.Stringent regulations by FDA for approval of new drugs also acts as a entry barrier for new players.
Bargaining power of buyers: The bargaining power of buyers is moderate as basal insulins have no substitute and buyers cannot shift to other therapeutics. However, presence of many manufacturers provides options to buyers.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of substitutes and less differentiation in raw materials. Suppliers do not influence pricing.
Threat of new substitutes: Threat of new substitutes is low as basal insulin has no close substitute. New drug development requires huge costs and time for clinical trials and approval.
Competitive rivalry: The competitive rivalry is high due to presence of many global and regional players. Players compete on basis of drug efficacy, innovative drug delivery mechanisms and regional expansion.
Geographical Regions
In terms of value, North America accounts for more than 40% share of basal insulin market due to high diabetic population and supportive reimbursement structure. Europe and Asia Pacific follow North America owing to growing geriatric population vulnerable to diabetes.
The fastest growing region for basal insulin market is Asia Pacific due to increasing diabetic incidences, rising healthcare spending and expanded access to diagnosis and treatment. Rising awareness about diabetes management and economic growth boost adoption of basal insulin therapeutics in Asia Pacific region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.
